Celgene International SÃ rl, a wholly owned subsidiary of Celgene Corp.announced that the European Commission or EC has approved ABRAXANE
(paclitaxel formulated as albumin-bound nanoparticles, or
nab-paclitaxel) in combination with carboplatin for the first-line
treatment of non-small cell lung cancer in adult patients who are not
candidates for potentially curative surgery and/or radiation therapy.
The ABRAXANE Marketing Authorisation has been updated across 28
member states in the European Union to include this new indication in
non-small cell lung cancer (NSCLC), adding to the existing indications
for the treatment of metastatic pancreatic and breast cancers.
Lung cancer is the fourth most commonly diagnosed cancer in
both men and women, however it is the leading cause of cancer-related
mortality in Europe. Non-small cell lung cancer (NSCLC) is the most
common form of lung cancer, accounting for 85 to 90% of all cases. The
predominant cause of lung cancer is cigarette smoking, although
environmental and occupational factors also can cause the cancer.
No comments:
Post a Comment